Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arrowhead Pharma (ARWR)

Arrowhead Pharma (ARWR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Arrowhead Pharma 177 E. Colorado Blvd Suite 700 Pasadena CA 91105 USA

www.arrowheadpharma.com Employees: 711 P: 626-304-3400 F: 626-304-3401

Sector:

Medical

Description:

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company which develops novel drugs to treat intractable diseases primarily in the United States. The company's proprietary Dynamic Polyconjugate platform develops drugs based on the RNA interference mechanism which silences disease-causing genes. Its products include ARC-520, ARC-521, ARC-AAT, ARC-F12, ARC-HIF2 and ARC-LPA which are in different clinical trial phase. Arrowhead Pharmaceuticals, Inc., formerly known as Arrowhead Research Corporation, is headquartered in Pasadena, California.

Key Statistics

Overview:

Market Capitalization, $K 9,185,488
Enterprise Value, $K 9,213,818
Shares Outstanding, K 135,880
Float, K 130,037
% Float 95.70%
Short Interest, K 9,626
Short Float 7.08%
Days to Cover 5.33
Short Volume Ratio 0.63
% of Insider Shareholders 4.30%
% of Institutional Shareholders 62.61%

Financials:

Annual Sales, $ 829,450 K
Annual Net Income, $ -1,630 K
Last Quarter Sales, $ 256,470 K
Last Quarter Net Income, $ -23,750 K
EBIT, $ 98,350 K
EBITDA, $ 116,490 K

Growth:

1-Year Return 252.82%
3-Year Return 101.13%
5-Year Return -12.40%
5-Year Revenue Growth 842.66%
5-Year Earnings Growth 98.81%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.18 on 11/25/25
Next Earnings Date 02/09/26 [AMC]
Earnings Per Share ttm -0.08
EPS Growth vs. Prev Qtr 85.71%
EPS Growth vs. Prev Year 86.96%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 11/17/11

ARWR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -0.37%
Return-on-Assets % -0.12%
Profit Margin % -0.20%
Debt/Equity 0.51
Price/Sales 10.69
Price/Cash Flow 546.73
Price/Book 17.93
Book Value/Share 3.64
Interest Coverage -1.58
60-Month Beta 1.21
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar